AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

AbbVie已加入尝试开发减肥药物的制药集团行列，从丹麦Gubra公司获得了一种长效胰淀素类似物的许可，该交易价值超过22亿美元。

The licensing deal – which includes a $350 million upfront payment and up to $1.875 billion in development, commercial and sales milestone payments – focuses on GUB014295, currently in a phase 1 clinical trial.

该许可协议包括 3.5 亿美元的预付款以及高达 18.75 亿美元的开发、商业和销售里程碑付款，重点是目前处于一期临床试验阶段的 GUB014295。

The runaway success of weight-loss drugs based on GLP-1 agonists like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) – which achieved sales of $8 billion and $5 billion, respectively last year – has led to an explosion of new obesity candidates in the industry pipeline and new biotechs being formed around them..

基于GLP-1激动剂的减肥药物的巨大成功，例如诺和诺德的Wegovy（司美鲁肽）和礼来公司的Zepbound（替尔泊肽），去年分别实现了80亿美元和50亿美元的销售额，这促使行业管道中涌现出大量新的肥胖症候选药物，并围绕它们成立了新的生物技术公司。

Dozens of other candidates are in the clinical pipeline, as developers chase a market that analysts at Goldman Sachs have suggested could be worth $100 billion by 2030.

数十种其他候选药物正处于临床研发管线中，开发者追逐的这个市场，据高盛分析师预测，到2030年可能达到1000亿美元。

Gubra's primary business is in preclinical contract research services, but it has a fertile peptide-based drug discovery within metabolic and fibrotic diseases that has also generated several obesity candidates. That includes two which are partnered with

Gubra的主要业务是临床前合同研究服务，但其在代谢和纤维化疾病方面拥有丰富的基于肽的药物发现成果，这也产生了多个肥胖症候选药物。其中两个已与合作伙伴联手开发。

Boehringer Ingelheim

勃林格殷格翰

– an agonist of three as-yet-unidentified targets and an NPY2R agonist that was dropped after disappointing early-stage clinical testing – and a long-acting GLP-1 agonist being developed with

—— 一种针对三个尚未确定靶点的激动剂，以及一种在早期临床试验中表现令人失望后被放弃的NPY2R激动剂 —— 还有一种正在开发中的长效GLP-1激动剂，

Amylyx

艾米利克斯

.

。

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to AbbVie. Amylin is a hormone that gives a feeling of fullness in the brain that suppresses appetite, reduces food intake, and delays gastric emptying.

根据艾伯维公司的说法，GUB014295 是一种皮下注射的长效艾塞那肽激动剂，同时还能刺激降钙素受体。艾塞那肽是一种激素，能够在大脑中产生饱腹感，抑制食欲、减少食物摄入并延缓胃排空。

In a six-week, phase 1 study reported last year GUB014295 (also known as GUBamy) achieved 3% weight loss with a single dose.

在去年报道的一项为期六周的第一阶段研究中，GUB014295（也称为GUBamy）单剂量实现了3%的体重减轻。

Novo Nordisk is also addressing this target with

诺和诺德也在针对这一目标采取措施

CagriSema

呼叫信号

, a combination of long-acting amylin analogue cagrilintide and GLP-1 agonist semaglutide – which disappointed in its first phase 3 readout – and

，长效胰岛素类似物cagrilintide与GLP-1受体激动剂semaglutide的组合——其在首个三期临床数据中表现不佳——并且

amycretin

艾米克雷丁

, a combined amylin and GLP-1 agonist that has shown weight loss of up to 22% over 36 weeks in a phase 1b/2a trial in obese or overweight patients reported earlier this year.

，一种结合了艾米林和GLP-1的激动剂，在今年早些时候报告的一项针对肥胖或超重患者的1b/2a期试验中显示，在36周内体重减轻了高达22%。

'At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists,' said AbbVie's chief executive Robert Michael.

“在艾伯维，我们专注于在存在重大未满足需求的领域改变患者护理的未来，”艾伯维首席执行官罗伯特·迈克尔表示。

'Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.'

“我们与Gubra的合作标志着我们进入肥胖症领域，这一合作基于满足患者需求的潜力，同时也为我们的公司带来长期增长的引人注目的机会。”

With GUB014295 now partnered, Gubra's attention will switch to its next in-house obesity programme, UCN2, which has been shown to prevent the loss of lean muscle mass associated with GLP-1 agonists and other obesity therapies in preclinical testing.

随着GUB014295现已达成合作，Gubra的注意力将转向其下一个内部肥胖项目UCN2，该项目在临床前测试中已显示出能够防止与GLP-1激动剂及其他肥胖疗法相关的瘦肌肉质量损失。